Status:
UNKNOWN
Lipo-dox and Cyclophosphamide /5-Fluorouracil in Patients With Metastatic Breast Cancer
Lead Sponsor:
TTY Biopharm
Conditions:
Metastatic Breast Cancer
Eligibility:
All Genders
20+ years
Phase:
PHASE2
Brief Summary
To determine the overall objective response rate of pegylated liposomal doxorubicin （Lipo-Dox）combined with cyclophosphamide/5-FU as second-line treatment in patients with metastatic breast cancer.
Eligibility Criteria
Inclusion
- histologically proved breast cancer with metastatic disease
Exclusion
- life expectancy less than 3 months.
Key Trial Info
Start Date :
September 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
Estimated Enrollment :
47 Patients enrolled
Trial Details
Trial ID
NCT01451580
Start Date
September 1 2005
Last Update
October 13 2011
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
CGMH
Linko, Taiwan